Tiotropium is now delivered via two different inhaler devices: the original Handihaler 18 μg once daily, which uses a powder formulation; and the newer Respimat Soft Mist Inhaler (SMI) 5 μg once daily. It has been questioned whether the two devices can be assumed to have the same safety profile, although the TIOSPIR trial showed that tiotropium when administered via Respimat SMI 5 μg is not less safe than Handihaler 18 μg. Therefore, we have carried out a safety evaluation of tiotropium Handihaler 18 μg versus tiotropium Respimat SMI 5 μg and 2.5 μg, via systematic review and network metaanalysis of the currently available clinical evidence. The results of our meta-analysis with an extremely large number of patients analysed demonstrate that the safety profile of tiotropium HandiHaler is generally superior to that of tiotropium Respimat SMI, although no statistical difference was detected between these two devices. However, the SUCRA analysis favoured tiotropium Respimat SMI with regards to serious adverse events (AEs). We do not believe that using Respimat SMI rather that HandiHaler exposes patients to higher risks of real AEs. Rather, we believe that there may be a different cardiovascular (CV) response to muscarinic receptors blockage in individual patients. Therefore, it will be essential to make all possible efforts to proactively identify patients at increased risk of CV AEs when treated with tiotropium or another antimuscarinic drug.
Introduction
There is well-built evidence indicating that tiotropium bromide is important in the maintenance treatment of chronic obstructive pulmonary disease (COPD) [Matera et al. 2014] . In fact, several large controlled trials have allowed documenting that this long-acting antimuscarinic agent not only improves lung function and reduces dyspnoea and rescue medication use in patients with COPD, but also impacts positively on health-related quality of life and reduces the risk of exacerbations, including those that require hospitalization [Keating, 2012; Karner et al. 2012 ].
However, concerns have been raised about the possible associations of tiotropium with cardiovascular (CV) morbidity and mortality [Singh et al. 2008] , although a lot of data that have been generated since the publication of the first concerns were reassuring on the CV safety of tiotropium in COPD patients [Cazzola et al. 2010 ]. In particular, Celli and colleagues [Celli et al. 2010] revised 30 trials lasting at least 4 weeks, in which overall 10,846 patients received tiotropium, and documented a significant reduction in the risk of a major or even fatal CV event in the tiotropium group compared with the placebo group. Furthermore, a post hoc analysis of all-cause mortality and serious cardiac adverse events (AEs) in patients who suffered from cardiac arrhythmia, myocardial infarction (MI) or cardiac failure during the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) study and completed the study, documented that tiotropium did not increase the risk of a major or even fatal CV event, following the occurrence of a cardiac event .
Tiotropium is now delivered via two different inhaler devices: the original Handihaler 18 μg once daily, which uses a powder formulation, and the newer Respimat Soft Mist Inhaler (SMI) 5 μg once daily. Respimat SMI delivers a higher fineparticle dose and allows higher drug deposition in the lung compared with aerosols produced by HandiHaler [Cazzola and Rogliani, 2015] . Remarkably, tiotropium HandiHaler 18 μg and Respimat SMI 5 μg have similar pharmacokinetic profiles. A recent extensive comparative pharmacokinetic and bronchodilator efficacy study in patients with COPD demonstrated a lower exposure but similar bronchodilator efficacy of oncedaily tiotropium Respimat SMI 5 µg compared with tiotropium HandiHaler 18 µg [Hohlfeld et al. 2014 ].
Nonetheless, it has been questioned whether the two devices can be assumed to have the same safety profile [Cates, 2011] . In fact, Singh and colleagues [Singh et al. 2011 ] reported a 46% relative increase in risk of mortality from any cause in patients using the mist inhaler compared with placebo [relative risk 1.46, 95% confidence interval (CI) 1.01-2.10]. Furthermore, a Cochrane review, which used the Peto method for pooled estimation of odds ratio, suggested that tiotropium Respimat but not tiotropium HandiHaler significantly increases the risk of mortality [Karner et al. 2012] . Another direct treatment comparison meta-analysis of randomized controlled trials (RCTs) confirmed that tiotropium Respimat SMI increases the risk of death compared with tiotropium HandiHaler [Dong et al. 2013] . Although the massive Tiotropium Safety and Performance in Respimat (TIOSPIR) trial showed that tiotropium when administered via Respimat 5 μg is not less safe than Handihaler 18 μg ], a large real-life study showed that use of tiotropium Respimat SMI was associated with an almost 30% increase of mortality compared with HandiHaler and the association was the strongest for CV/cerebrovascular death [Verhamme et al. 2013] . Therefore, it has been suggested that the administration of tiotropium via Respimat SMI should be avoided in patients with pre-existing CV comorbidities [Mathioudakis et al. 2014 ] and, more recently, also chronic kidney disease because of the renal excretion of tiotropium [Mathioudakis et al. 2015] .
Therefore, in view of the patent dichotomy between what documented by the TIOSPIR study and the results of initial meta-analyses and the real-life study, we have carried out a safety evaluation of tiotropium Handihaler 18 µg versus tiotropium Respimat SMI 5 µg and 2.5 µg, via systematic review and network meta-analysis of the currently available clinical evidences.
Meta-analysis
Methods A network meta-analysis was performed in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement (Figure 1) [Moher et al. 2009 ].
Data sources and searches. Published and unpublished RCTs were searched in PubMed and Google Scholar (there is now agreement that for quick clinical searches, Google Scholar returns twice as many relevant articles as PubMed and provides greater access to free full-text articles [Shariff et al. 2013] ) through June 2016, and citations of a previous published pooled-analyses was examined to identify further pertinent studies, if any [Halpin et al. 2015 ]. The terms "tiotropium" AND "Handihaler" AND/OR "Respimat" were searched.
Study selection. RCTs lasting at least 2 weeks and reporting the safety of tiotropium administered in COPD patients via Handihaler 18 µg or Respimat 5 µg and 2.5 µg, compared with inhaler containing matching placebo, were selected. Studies that have directly compared Handihaler 18 µg versus Respimat 5 µg and 2.5 µg have been also selected.
Data extraction and quality assessment. Two reviewers independently checked the relevant RCTs found from literature, and any difference in opinion about eligibility was resolved by consensus.
Data from included studies were extracted and checked for study characteristics and duration, number of enrolled patients, doses of tiotropium, disease characteristics, and AEs. The Jadad score, with a scale of 1-5 (score of 5 being the highest), was used to assess the quality of the RCTs concerning the likelihood of bias related with randomization, double blinding, withdrawals and dropouts [Calzetta et al. 2016a and 2016b] .
The effect of study quality was examined by excluding trials with a Jadad score <3. The risk of publication bias was assessed by Egger's test [Rogliani et al. 2016] .
Data synthesis and analysis. The endpoint of this network meta-analysis was to compare the safety profile of tiotropium with regard of HandiHaler and Respimat inhalers by analysing the occurrence of AEs, serious adverse events (SAEs) and risk of death in COPD patients.
The network meta-analysis was performed by using a full Bayesian evidence network (chains: 4; initial values scaling: 2.5; tuning iterations: 20,000; simulation iterations: 50,000; tuning interval: 10), the convergence diagnostics for consistency and inconsistency was assessed by using the Brooks-Gelman-Rubin method [Calzetta et al. 2016 a and 2016b] . Results of network metaanalysis have been expressed as relative effect and 95% credible level (CrI). Due to the complex evidence network, the inconsistency of evidence has been assessed by inconsistency factor (IF), indicating whether one of the treatment has a different effect when it is compared with the others [Mavridis et al. 2015] . The probability that each intervention arm was the most effective was calculated by counting the proportion of iterations of the chain in which each intervention arm had the highest mean difference, and the surface under the cumulative ranking curve (SUCRA), representing the summary of these probabilities, was also calculated [Calzetta et al. 2016a and 2016b] . The SUCRA is 100% when a treatment is certain to be the best, and 0% when a treatment is certain to be the worst [Calzetta et al. 2016a and 2016b] .
The optimal information size (OIS) was calculated as previously reported [Rogliani et al. 2016] , and the statistical significance was assessed for p < 0.05. Evidence of asymmetry from Egger's test was considered to be significant for p < 0.1, and the graphical representation of 90% confidence bands have been presented [Calzetta et al. 2016a and 2016b]. GeMTC [Van Valkenhoef et al. 2012] was used for performing the network meta-analysis, and GraphPad Prism (CA, USA) software to graph the data.
Results

Study characteristics and OIS
Results obtained from 43,286 COPD patients (tiotropium HandiHaler 18 µg n = 16,016, tiotropium Respimat 5 µg n = 9,750, tiotropium Respimat 2.5 µg n = 5,889, matching placebo n = 11,631) were selected from 38 published and unpublished studies including 44 RCTs [Casaburi et al. 2002 [Casaburi et al. , 2005 Donohue et al. 2002; Brusasco et al. 2003; Calverley et al. 2003; Celli et al. 2003; Mcnicholas et al. 2004; O'Donnell et al. 2004; Covelli et al. 2005; Maltais et al. 2005; Niewoehner et al. 2005; Beeh et al. 2006; Dusser et al. 2006; Verkindre et al. 2006; Caillaud et al. 2007; Chan et al. 2007 , Freeman et al. 2007 Garcia, 2007; Powrie et al. 2007; Ambrosino et al. 2008; Criner et al. 2008; Johansson et al. 2008; Magnussen et al. 2008; Moita et al. 2008; Tashkin et al. 2008; Tonnel et al. 2008; Voshaar et al. 2008; Bateman et al. 2010a, b; Ichinose et al. 2010; Sciurba et al. 2011; Fuhr et al. 2012; Abrahams et al. 2013; Cooper et al. 2013; Wise et al. 2013; Troosters et al. 2014; Beeh et al. 2015; Singh et al. 2015; Bouloukaki et al. 2016] , between 2002 and 2016 ( Figure 2 ).
The relevant patient demographics, study characteristics, and Jadad score have been summarized in Table 1 . The period of treatment ranged from 2 to 208 weeks, and two studies were assessed as having a Jadad score <3 [Garcia, 2007; Bouloukaki et al. 2016 ].
The number of COPD patients from the selected RCTs permitted to carry out a meta-analysis with a reasonable OIS to ensure a very good (probability of observing 20% overestimation for τ 2 = 0.25: <5% at true relative risk reduction 10%) low risk of observing an overestimated intervention effect due to random errors in scenarios where the control group risk was low (1-5%).
Safety profile of tiotropium Handihaler versus tiotropium Respimat
The network meta-analysis did not indicate any significant difference (p > 0.05) between the safety profile of tiotropium HandiHaler 18 µg and tiotropium Respimat 5 µg or 2.5 µg. However, the resulting relative effects were overall in favour of tiotropium HandiHaler than Respimat, with regard of AEs, SAEs and risk of death ( Figure  3A ). These results have been also confirmed by the subset analysis carried out by excluding the RTCs with Jadad score <3 (p > 0.05 versus network meta-analysis including all of the RCTs).
The analysis of inconsistency indicated that no discrepancy exists between direct and indirect evidences (AEs IF 0.01, 95% CrI −0.93 to 0.87; p > 0.05; SAEs IF 0.01, 95% CrI −0.38 to 0.81, p > 0.05; risk of death IF 0.03, 95% CrI −2.65 to 1.94. p > 0.05). The Egger's test did not find any asymmetry (p > 0.1), suggesting that no publication bias was present in this network meta-analysis ( Figure 3B ). Tiotropium HandiHaler 18 µg showed highest probability of being the best therapy with regard of AEs and risk of death (66% and 30%, respectively), as confirmed by SUCRA (87% and 61%, respectively), whereas tiotropium Respimat SMI 5 µg had the highest probability of being the best therapy with regard of SAEs (Table 2 ). In fact, the incidence of the most frequently reported CV SAEs such as cardiac failure, MI, and fibrillation was greater in patients receiving tiotropium HandiHaler (Table 3 ). 
Discussion
In recent years, several reviews and pooled safety analysis, probably not entirely independent because they include authors who are employees of the drug company that manufactures and markets tiotropium Respimat SMI and HandiHaler and therefore with a potential conflict of interest, indicate that tiotropium, given via either HandiHaler or Respimat SMI, does not increase the overall risks of AEs, SAEs, fatal AEs, or CV events [Halpin et al. 2015] . Furthermore, two post hoc analyses of TIOSPIR study have respectively demonstrated that tiotropium Respimat SMI and HandiHaler have similar safety and efficacy profiles in patients who are naïve to anticholinergic therapy [Wise et al. 2015] and it is safe to switch patients from tiotropium HandiHaler to tiotropium Respimat SMI also because the efficacy is maintained over the switch .
The results of this independent network metaanalysis demonstrate that the safety profile of tiotropium HandiHaler is generally superior to that of tiotropium Respimat SMI, although no statistical difference was detected between these two devices.
Remarkably, the SUCRA analysis favoured tiotropium Respimat SMI with regards to SAEs. In fact, the incidence of the most frequently reported CV SAEs such as cardiac failure, MI, and fibrillation was greater in patients receiving tiotropium via HandiHaler. However, the results obtained by the SUCRA analysis should be interpreted with caution, because the relative effect estimate for SAEs was mainly centred between tiotropium HandiHaler 18 µg and tiotropium Respimat SMI 5 µg.
In any case, despite the large CrI values, the risk of death was always smaller for tiotropium HandiHaler than tiotropium Respimat SMI.
As expected, the extremely large number of patients analysed in this network meta-analysis has completely abolished any publication bias, regardless of the quality of the RCTs included in the analysis.
To the best of the authors' knowledge, this is the first network meta-analysis aimed to investigate the safety profile of tiotropium Handihaler versus tiotropium Respimat SMI. Indeed, this study represents the natural step-forward from a recent pooled analysis [Halpin et al. 2015 ] that, inexplicably, did not include the data from RCTs in which the direct comparison between tiotropium Handihaler and tiotropium Respimat was performed, such as the studies of Bouloukaki and colleagues [Bouloukaki et al. 2016] , Ichinose and colleagues [Ichinose et al. 2010] , and Wise and colleagues , the latter being the largest RCT with >17,000 COPD patients treated with tiotropium for 2.3 years.
The trend towards a better safety profile of tiotropium HandiHaler compared with tiotropium Respimat SMI is difficult to be explained, given the repeated documentation of a systemic exposure for the two devices within the margins of equivalence [van Noord et al. 2009; Ichinose et al. 2010; Hohlfeld et al. 2014 ]. These pharmacokinetic data do not support the hypothesis proposed by Singh and colleagues [Singh et al. 2011 ] that the Respimat SMI results in earlier systemic exposure to, and higher plasma concentrations of, tiotropium after dosing increasing the risk of anticholinergic CV effects (arrhythmia). In any case, a study that analysed all data from the tiotropium clinical trial database involving Holter-ECG monitoring in patients with COPD did not show any clinically relevant differences between Respimat SMI and HandiHaler with respect to changes in heart rate or in the proportion of patients experiencing supraventricular or ventricular premature beats while on tiotropium [Hohlfeld et al. 2015] .
The unexpected finding of our meta-analysis is the evidence that the incidence of the most frequently reported CV SAEs such as cardiac failure, MI, and fibrillation was greater in patients receiving tiotropium HandiHaler. In any case, it is important to highlight that we found a low absolute risk of CV AEs with both devices (Table 3) .
It is obvious, at this point, to wonder whether the possible occurrence of AEs is linked to a particular genetic predisposition never investigated until now (modification of Regulator of G-protein signalling 6 (RGS6) [Patanè, 2015] ) rather than to a specific device, emphasizing the need for further studies in a real-world setting to identify high-risk patients that may benefit from ECG surveillance.
In any case, it is now documented that M3 muscarinic receptor overexpression reduces the incidence of arrhythmias and mortality after myocardial ischemia-reperfusion by protecting the myocardium from ischemia at least in mice [Liu et al. 2011] . The protective mechanism of this receptor is rather complex. It regulates heart rate and cardiac repolarization, modulates inotropic effects, elicits cytoprotection against ischaemic injuries of myocardium, and regulates cell-to-cell communication [Wang et al. 2007 ]. Intriguingly, the expression of M3 muscarinic receptors appears to be increased in patients with atrial fibrillation, atrial dilatation, congestive heart failure, ventricular myocardial ischemia, and cardiac hypertrophy [Patanè, 2014] . Is it possible that changes in this overexpression can induce different responses to the blockade of muscarinic receptors operated by antimuscarinic drugs? In fact, all of the antimuscarinic drugs can cause more or less serious CV AEs [Sing et al. 2008; Matera et al. 2014 ].
We do not believe that using Respimat SMI rather that HandiHaler exposes patients to higher risks of real AEs. Rather, we believe that there may be a different CV response to muscarinic receptors blockage in individual patients. Therefore, it will be essential to make all possible efforts to proactively identify patients at increased risk of CV AEs when treated with tiotropium or another antimuscarinic drug.
In any case, we cannot forget this is a potentially dangerous occurrence, and health care providers need to be advised before incorporating antimuscarinic drugs in the management of COPD. 
